Biological E Limited has received Phase II prequalification from the World Health Organization for its Novel Oral Polio Vaccine type 2, strengthening global supply and boosting efforts to control vaccine-derived polio outbreaks worldwide.
Bharat Biotech is exploring a new biologics manufacturing facility near Chennai, aiming to produce advanced therapies including monoclonal antibodies and diabetes treatments as part of its long-term growth strategy.
Cipla Foundation and IISc have launched a Centre for Pulmonary Medicine in Bengaluru, offering advanced care, research, and training to tackle India’s rising respiratory health challenges.
Dabur India today inaugurated its first south Indian manufacturing plant in Tindivanam, Tamil Nadu. The Rs 400 crore facility will produce popular personal care products and drive local employment.
Sanofi has finalized its acquisition of Dynavax, adding hepatitis B vaccine HEPLISAV-B and a shingles vaccine candidate to its portfolio. The $15.50 per share deal strengthens Sanofi’s position in adult immunization.
USV Pharma is in advanced talks to acquire an 85% stake in Wellbeing Nutrition at a Rs 1,600 crore valuation, marking a major move into India’s fast-growing consumer health and supplements market.
.jpeg "Aurobindo Pharma's Biosimilar Growth to Peak by 2029, CEO Says")
Aurobindo Pharma aims for significant biosimilar growth by 2029, with approved oncology products and strategic plans for Europe and Latin America markets, says CEO Satakarni Makkapati.
Kashiv BioSciences has signed an exclusive licensing and supply agreement with Intas Pharmaceuticals to commercialize a complex peptide product across Europe, the UK, and India, expanding its global footprint.
Sanofi has received FDA breakthrough therapy designation for Wayrilz to treat warm autoimmune hemolytic anemia, a rare disorder with no approved targeted therapies. Japan has also granted orphan status.
Natco Pharma has received High Court approval to manufacture and export semaglutide, strengthening its entry into the global diabetes and obesity drug market and expanding its presence in metabolic disorder treatments.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")